Chinese technology group Huawei launched an “AI+ healthcare” initiative to apply artificial intelligence (AI) to clinical workflows and medical research. It will focus on pathology, where digital systems can reduce delays, support remote diagnosis and improve collaboration between specialists. – BusinessDay (5 March 2026)
According to Huawei the model covers 19 common cancer types representing about 90% of annual cancer cases in China.
Huawei claims the solution enables second-level access to more than 1,000 pathological sections reducing storage use by 45% and boosts diagnostic efficiency when handling large volumes of digital slides.
Meanwhile, Netcare, one of the country’s largest private hospital groups, plans to introduce medical-grade wearable devices to monitor patients’ vital statistics using AI.